Type 2 diabetes is causally associated with depression: a Mendelian randomization analysis
Dual GLP-1/GIP receptor agonists possess distinct pharmacodynamic and metabolic profiles, and long-term oncological safety data for these agents remain limited
Exercise during GLP-1 therapy supports muscle preservation, improves metabolic health, and enhances overall wellbeing
Switching from tirzepatide A growing number of researchers are transitioning from tirzepatide to retatrutide, typically because they have hit a tirzepatide weight loss plateau or want to push past the weight loss ceiling of dual agonism
In some situations, GLP-1 medications and bariatric surgery may be used together as part of a broader long-term treatment plan
Clinicians and patients should interpret Phase 2 data with appropriate caution, as larger and longer studies may reveal additional safety signals